Genmab — Oktober 2018
-
CheckMate-331 nåede ikke i mål: https://markets.businessinsider.com/news/stocks/bristol-myers-says-phase-3-chec
kmate-331-study-fails-to-meet-primary-endpoint-1027612295 -
-
Stakkels de mennesker der solgte BMS for 2 dage siden. De får nok snart besøg af nogen de ikke ville bryde sig om at få besøg af....
-
Altid godt med stigning under stor omsætning.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind